Accelerating Medicines Partnership for Common Metabolic Diseases (AMP-CMD)
NIDDK Participation in NIH’s Accelerating Medicines Partnership (AMP)
NIDDK is the NIH partner in the Accelerating Medicines Partnership for Common Metabolic Diseases (AMP-CMD). Partnering with biopharmaceutical companies and non-profit organizations, this new public-private partnership, managed through the Foundation for the National Institutes of Health (FNIH), is aimed at identifying promising new targets for six common metabolic diseases: nonalcoholic steatohepatitis, kidney diseases, obesity, cardiovascular diseases, type 2 diabetes/prediabetes, and type 1 diabetes.
NIDDK-funded projects will leverage existing genomic association data and integrate new functional genomic data to achieve the following:
- Systematic identification of causal variants at genomic loci associated with common metabolic diseases
- Prioritization of likely effector transcripts functioning at associated genomic loci
- Validation of the role of effector transcripts in disease phenotypes in relevant tissues and cell types
- Generation of pathway networks that incorporate effector transcripts and other genes to clarify their roles in metabolic diseases and to identify common pathways across the diseases
- Creation of data analysis tools to increase usability of large scale functional genomic data generated
- Make all data and analytical tools generated accessible for public use via the online CMD Knowledge Portal
AMP-CMD brings together four biopharmaceutical companies with four teams of NIDDK-funded investigators, including a Knowledge Portal team and Data Coordinating Center. The consortium will capitalize on the enormous amounts of existing genomic data and will generate new largescale molecular data to achieve a deep understanding of genes and pathways that underlie metabolic diseases. Using this information, the consortium will identify and integrate datasets to identify potential biotargets and new therapeutic targets.
- NIH - NIDDK
- Eli Lilly and Company
- Novo Nordisk
- Pfizer Inc.
- Foundation for the NIH
NIDDK has solicited participation through the following funding opportunities for AMP
- Limited Competition for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Knowledge Portal (RFA-DK-19-505)
- Understanding the Functional Contributions and Mechanisms of Type 2 Diabetes Disease-associated Variants (RFA-DK-19-012)
About NIH's AMP initiative
The Accelerating Medicines Partnership is a public-private partnership that incorporates NIH, FDA, biopharmaceutical and life science companies, and non-profit organizations across multiple disease-focused projects. The goal of the partnership in each project is to accelerate the identification of new diagnostics and therapies through expertise and resources shared among partners.
NIDDK Program Staff
- Norann Zaghloul, Ph.D. Genetics and genomics of Type 2 diabetes and functional genomic studies in Type 2 diabetes and metabolic diseases
Recent Funding OpportunitiesView More Recent Funding Opportunities
Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)
Launching Future Leaders in Global Health (LAUNCH) Research Training Program (D43 Clinical Trial Optional)
NIDDK Short-Term Research Experience Program to Unlock Potential (STEP-UP) (R25 Clinical Trial Not Allowed)
Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations RADx-UP Phase II (U01 Clinical Trial Optional)
Emergency Award: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional)
View related clinical trials from ClinicalTrials.gov.
Study sections conduct initial peer review of applications in a designated scientific area. View related study sections from the NIH's Center for Scientific Review.
NIDDK makes publicly supported resources, data sets, and studies available to researchers to accelerate the rate and lower the cost of new discoveries.
- Ancillary Studies to Major Ongoing Clinical Studies to extend our knowledge of the diseases being studied by the parent study investigators under a defined protocol or to study diseases and conditions not within the original scope of the parent study but within the mission of the NIDDK.
- NIDDK Central Repository for access to clinical resources including data and biospecimens from NIDDK-funded studies.
- NIDDK Information Network (dkNET) for simultaneous search of digital resources, including multiple datasets and biomedical resources relevant to the mission of the NIDDK.
Additional Research Programs
NIDDK supports the training and career development of medical and graduate students, postdoctoral fellows, and physician scientists through institutional and individual grants.Learn about NIDDK Research Training Programs
The NIDDK offers and participates in a variety of opportunities for trainees and researchers from communities underrepresented in the biomedical research enterprise. These opportunities include travel and scholarship awards, research supplements, small clinical grants, high school and undergraduate programs, and a network of minority health research investigators.Learn about NIDDK Diversity Programs
NIDDK participates in the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. These programs support innovative research conducted by small businesses that has the potential for commercialization.Learn about NIDDK Small Business Programs
Human Subjects Research
NIDDK provides funding for pivotal clinical research, from preliminary clinical feasibility to large multi-center studies.Learn about Human Subjects Research
NIDDK provides funding opportunities and resources to encourage translation of basic discoveries into novel therapeutics.Learn about NIDDK Translational Research Opportunities
Meetings & Workshops
Supports researchers with tools to enhance scientific rigor, reproducibility, and transparency, and provides a big data knowledge base for genomic and pathway hypothesis generation.
Providing education and training for the next generation of biomedical and behavioral scientist